Innovation in gene therapies is hard, but also potentially ground-breaking and biotechnology firm Medera is taking its decades-long journey in the space to the public markets just as hits its next steps in the clinical process.
This week, we speak with Medera CEO Ronald Li, and Kenneth Wong, CEO and Chairman of Keen Vision Acquisition Corp. The two announced a $622 million dollar combination in September.
Ron explains how Medera has leveraged years of innovations including the capacity to grow miniature human hearts for testing as it advances gene therapies for heart failure that do not rely on animal testing and could prove significantly cheaper than alternatives.
Kenneth tells us why he believes those details align well with the changing regulatory and investment climate around drug development. And, why he views Medera as being a more mature investment play in the biotech space than many of the others coming to market today.
Give it a listen.
At the SPAC of Dawn Companies going public in SPAC mergers have gotten used to dips in stock price of some magnitude or another when their transactions close, but only recently have they attempted to be proactive in setting the narrative during such times. Retail technology firm Alpha Modus (NASDAQ:AMOD) recently put out an aggressive...
Archimedes Tech SPAC Partners II Co. (NASDAQ:ATIIU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ATIIU”, Tuesday, February 11, 2025. The new SPAC intends to search for a target company in the technology industry, with a particular focus on artificial intelligence,...
Goldman Sachs veteran Peter Ort headlines two new SPACs that filed for IPOs Friday in Real Asset Acquisition Corp. (NASDAQ:RAAQU) and Digital Asset Acquisition Corp. (NASDAQ:DAAQU), which collectively sport some of the most team-friendly terms yet seen in 2025. Both new SPACs have 1/4 warrants in their units and no rights, bringing a level of...
At the SPAC of Dawn The pace of new SPAC filings has not slackened as three new S-1s were filed on either end of Super Bowl weekend seeking a combined $500 million in IPO proceeds. All three are underwritten by Cohen & Company and feature anchor investors as well as promotes upsized to the equivalent...
Terms Tracker for the Week Ending February 7, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. This past week saw one new SPAC IPO price, bringing the year-to-date total to nine. K&F Growth Acquisition Corp. II successfully debuted and managed to...